Von Willebrand Disease and Pregnancy: How Hematology and Obstetrics Plan Delivery Together

The positive test sits on the bathroom counter, and the first feeling is joy. The second, a beat later, is a question that has nothing to do with nursery colors: what does my bleeding disorder mean for this baby and for me? For someone with von Willebrand disease, that question arrives early and tends to stay.

The reassuring answer is that this is one of the better-mapped situations in high-risk obstetrics. Von Willebrand disease pregnancy management has a clear logic to it, built on a quirk of biology: the body makes more clotting protein during pregnancy, then withdraws it fast after birth. Almost every decision follows from that curve.

What makes the difference is not a single drug or a single doctor. It is two specialties, hematology and obstetrics, sitting at the same table months before the due date, with anesthesia and the newborn team pulled in as the plan takes shape. This article walks through how that plan is built, what it usually contains, and where the evidence is firm or still thin.

Can you have a baby if you have von Willebrand disease?

Yes. Von Willebrand disease does not reduce fertility, and it does not prevent a healthy pregnancy or a vaginal birth. The condition is a bleeding disorder, so the questions it raises cluster around three moments: any bleeding during pregnancy, the birth itself, and the days and weeks that follow.

It helps to know how common the diagnosis is. The CDC and the NHS both describe von Willebrand disease as the most common inherited bleeding disorder, affecting up to about 1 in 100 people, although many have mild symptoms and are never formally diagnosed. Women are diagnosed more often than men, largely because heavy periods and bleeding after childbirth bring the problem to light.

Pregnancy is, in a sense, a stress test for the clotting system that most people never notice. Someone with a milder form may have gone decades with occasional nosebleeds and long periods, then face their first real bleeding risk in the delivery room. That is exactly why the planning described here exists.

The outcomes that matter most, a safe mother and a safe baby, are achievable in the large majority of pregnancies when the condition is known ahead of time and the team has a written plan. Mayo Clinic and the NHS both frame the condition as manageable rather than dangerous, provided the care team knows about it before labor begins. The danger lies in surprises: an undiagnosed mother, a rushed instrumental delivery, or a heavy bleed at home two weeks after discharge with nobody expecting it. Good management is mostly about removing the surprises.

What is von Willebrand disease, in plain language?

Von Willebrand factor is a large protein in the blood that works like a glue in the first seconds of clotting. When a vessel is injured, it helps platelets (the small cell fragments that plug a wound) stick to the damaged wall and to each other. It also carries and protects factor VIII, another clotting protein, so when von Willebrand factor is low, factor VIII often drifts low too.

Von Willebrand disease means the body either makes too little of this protein or makes a version that does not work properly. MedlinePlus describes three main inherited types:

• Type 1: less protein than normal, but the protein works. This is the most common form and is usually mild to moderate.
• Type 2: a normal or near-normal amount, but the protein is faulty. There are several subtypes (2A, 2B, 2M, 2N), each with a different flaw. Type 2B is unusual because the faulty protein grabs platelets too eagerly and can lower the platelet count.
• Type 3: almost no von Willebrand factor at all, with very low factor VIII. This is rare and causes the most serious bleeding.

A fourth, non-inherited form called acquired von Willebrand disease develops later in life because of another condition. It is covered in its own section below.

The everyday picture is bruising easily, nosebleeds that take a long time to stop, heavy or prolonged periods, bleeding gums, and prolonged bleeding after cuts, dental work or surgery. In pregnancy, the relevant feature is simple: the mother’s ability to form a stable clot where the placenta separates from the uterus depends in part on this protein, and the amount available changes dramatically over nine months.

Why von Willebrand disease pregnancy management starts before conception

The ideal first appointment for pregnancy planning happens before anyone is pregnant. A preconception visit with a hematologist (a doctor who specializes in blood disorders) lets the team confirm the exact type and subtype, record baseline clotting levels, and check how the person responded in the past to the medicines commonly used for the condition.

Three things get settled early. First, the type. The plan for type 1 looks different from the plan for type 2B or type 3, as the table later in this article shows. Second, a desmopressin trial, if it has never been done. Desmopressin is a synthetic version of a natural hormone that prompts the body to release its stored von Willebrand factor. A supervised test dose, given outside pregnancy, shows whether that release is large enough to be useful. People with type 3 have little to release, and desmopressin is generally avoided in type 2B because it can drop the platelet count further, according to the ASH, ISTH, NHF and WFH guideline published in Blood Advances. Third, genetic counseling, so the parents understand how the condition could pass to a child.

Preconception review also catches practical issues. Iron stores are often low in people with years of heavy periods, and anemia going into pregnancy makes any later bleed harder to tolerate. Someone on long-term hormonal treatment for heavy periods will need to discuss timing with the prescribing clinician; this article does not advise starting or stopping any medicine.

Not everyone gets this head start. Many pregnancies are unplanned, and some people are diagnosed only when bleeding complicates the pregnancy itself. The system is designed to catch up quickly, but the earlier the referral, the more options the team has and the calmer the delivery tends to be.

How does pregnancy change von Willebrand factor levels?

Here is the mechanism that drives the whole plan. During a normal pregnancy, levels of von Willebrand factor and factor VIII climb steadily, driven by hormonal changes and increased production by the lining of blood vessels. By the third trimester they are often two to three times the person’s pre-pregnancy baseline. This is the body preparing for the bleeding challenge of birth.

In type 1 disease, where the protein works but is in short supply, this natural rise often lifts levels into the normal range by the time labor begins. Many people with mild type 1 need no specific treatment for a vaginal birth for exactly this reason, a point made in both the NHS guidance and the international guideline.

The pattern is less helpful in type 2. More protein is produced, but it is still faulty, so the functional measure (how well the protein actually works) may stay low even as the total amount rises. In type 2B, the extra faulty protein can pull more platelets out of circulation, so the platelet count may fall as pregnancy advances. In type 3, there is little capacity to make the protein at all, and levels stay low throughout.

Then comes the part that catches people out. After delivery, levels fall back toward baseline within days to a few weeks. The international guideline describes this decline as the reason the postpartum period, not the birth itself, carries the longest window of bleeding risk for someone with von Willebrand disease. Hematology teams therefore think of the plan as a curve, not a single number: supported through labor, and watched closely as the natural protection ebbs away.

Because of this curve, a level drawn in the first trimester tells the team relatively little about delivery. The number that matters is the one drawn late in pregnancy.

Who needs an intensive plan, and who can usually follow a lighter path

Not everyone with von Willebrand disease needs the same intensity of care, and the specialty literature is careful to say so. The team sorts people by type, by measured levels in late pregnancy, and by personal bleeding history.

The lighter path usually applies to someone with type 1 whose functional levels have risen into the normal range by the third trimester and who has no history of severe bleeding. The international guideline suggests that when von Willebrand factor activity and factor VIII reach at least 50 international units per deciliter, often written as 0.50 IU/mL, specific treatment to raise levels is generally not required for delivery. Care is still shared, and the postpartum watch still applies, but the birth itself may look much like any other.

The intensive path applies to people with:

• Type 3 disease, where levels remain very low regardless of pregnancy.
• Type 2 subtypes where functional measures stay low despite a rising total protein level, and especially type 2B with a falling platelet count.
• Type 1 whose levels do not rise as expected, which happens in a minority and is one reason the late-pregnancy test is essential.
• A personal history of major bleeding after previous births, surgery or dental work, whatever the laboratory numbers say.

Who is asked to wait? In this context, waiting usually means delaying decisions rather than delaying pregnancy. Someone referred late may be asked to hold off on an epidural decision until a fresh level is available. Someone with a planned cesarean for other reasons may have the date adjusted so that treatment can be timed properly. Any decision about whether to conceive, or when, sits with the person and their clinicians, not with a flowchart.

How hematology and obstetrics build the delivery plan together

The phrase that appears in nearly every guideline on this topic is multidisciplinary planning. In practice it means a small, named group: a hematologist, an obstetrician experienced with high-risk pregnancy, an obstetric anesthesiologist (the specialist who manages pain relief and anesthesia during birth), and a pediatric or neonatal clinician for the baby. Often a specialist nurse or midwife coordinates between them.

The plan is usually written down and placed in the maternity record so that whoever is on duty at 3 a.m. can read it. A typical document covers:

• The confirmed type and subtype, and the most recent functional levels.
• Which medicine, by class, will be used if levels need raising, and when it would be given relative to labor or a planned cesarean.
• Whether desmopressin is appropriate for this person, and if not, why.
• The anesthetic plan, including the threshold the anesthesiologist wants before a neuraxial block (an epidural or spinal injection near the spinal cord).
• Fetal precautions, such as avoiding certain monitoring devices and instrumental delivery methods.
• Postpartum medicines, monitoring schedule, and who to call.

Timing drives the schedule. The hematologist usually requests a repeat set of levels in the third trimester, often around weeks 34 to 36, so the figures reflect what the body will have on the day. The NHS describes this late check as standard practice. If a planned cesarean is needed for obstetric reasons, the team often prefers to schedule it so that treatment can be given shortly beforehand and daytime laboratory support is available.

The obstetrician contributes the practical reality of birth: the likelihood of induction, the chance of a cesarean, and how fast things might move. The hematologist contributes the numbers and the treatment logic. Neither plan works alone, which is why the two specialties are asked to co-author rather than consult sequentially.

Which treatments are used, and how do they actually work?

Three classes of medicine come up repeatedly. Each addresses a different weak point in clotting, and the choice depends on type, measured levels and the stage of labor. No figures for doses or amounts appear here, because those belong to the prescribing clinician.

Desmopressin is a synthetic hormone that tells the cells lining blood vessels to release their stored von Willebrand factor and factor VIII into the circulation. It works only if there is a store to release, which is why it suits many people with type 1 and some with type 2, and generally not those with type 3. The guideline cautions against its use in type 2B because the released faulty protein can lower platelets. It also causes the body to retain water, so fluid intake is restricted around the time it is given, and hematologists are cautious about repeated use. Its effect is temporary, lasting hours rather than days, which matters for the long postpartum window.

Von Willebrand factor concentrates are purified or laboratory-made versions of the protein itself, given by infusion. They work regardless of type because they replace what is missing or faulty. They are the mainstay for type 3, for type 2B, for anyone who does not respond to desmopressin, and for situations where levels must be held up for several days, such as after a cesarean.

Tranexamic acid belongs to a class called antifibrinolytics. Once a clot has formed, the body naturally starts dissolving it; this medicine slows that dissolving process so the clot holds longer. It does not raise von Willebrand factor at all, which is why it is often used alongside the other two, and the international guideline suggests it for the postpartum period to reduce the risk of delayed bleeding.

Which of these a person receives, and whether they receive any, is decided by the treating team based on the late-pregnancy levels and the delivery plan.

A summary table: how type changes the plan

The table below pulls together the main threads. It describes typical considerations drawn from guideline-level sources, not a prescription for any individual. Every row has exceptions, and the treating team’s assessment overrides any general pattern.

Type	What is wrong	How pregnancy usually affects levels	Typical treatment approach, if needed	Points the team watches
Type 1	Too little protein; protein works normally	Levels often rise into the normal range by the third trimester	Often no treatment for vaginal birth if levels are adequate; desmopressin or concentrate if not; antifibrinolytic after birth is commonly considered	Confirm the rise actually happened with a late test; postpartum fall
Type 2 (A, M, N)	Protein present but faulty	Total protein rises; functional measure may stay low	Concentrate more often needed; desmopressin only if a prior trial showed a useful response	Functional assays, not just total amount; type 2N can look like a factor VIII problem
Type 2B	Protein binds platelets too readily	Platelet count may fall as pregnancy progresses	Concentrate; desmopressin generally avoided	Platelet count trend; anesthesia planning is more complex
Type 3	Almost no protein	Little or no rise	Concentrate before and after delivery; antifibrinolytic alongside	Planned delivery timing; prolonged postpartum cover; baby may inherit the condition
Acquired	Protein consumed or destroyed by another condition	Depends on the underlying cause	Treat the cause; concentrate or other measures case by case	Rare in pregnancy; needs specialist input

Two features deserve emphasis. First, the right-hand columns matter more than the left: a person with type 1 whose levels fail to rise may need more support than the type label suggests. Second, the postpartum row is missing because it applies to everyone. Whatever the type, the natural protection of pregnancy fades after birth, and the plan for that period is as important as the plan for labor.

Can you have an epidural with von Willebrand disease?

Often, yes, but it is one of the decisions the team takes most seriously. An epidural involves placing a fine catheter in the space just outside the spinal cord’s protective covering; a spinal injection goes one layer deeper. Either can, very rarely, cause bleeding in that confined space. In a person with normal clotting the risk is tiny. In someone with low von Willebrand factor it is higher, and a clot pressing on the spinal cord is a surgical emergency.

The international guideline from the hematology societies suggests that neuraxial anesthesia can be offered when von Willebrand factor activity and factor VIII levels are at least 0.50 IU/mL at the time of the procedure, and that levels should be kept at or above that threshold while the catheter is in place and for a period after it is removed. For many people with type 1 whose levels have risen naturally, this condition is met without treatment. For others, it is met by giving concentrate or desmopressin beforehand. For some, particularly with type 2B and a low platelet count or with type 3 and unpredictable levels, the anesthesiologist may advise against a neuraxial block and discuss alternatives such as intravenous pain relief or, for cesarean, general anesthesia.

What this means practically: the anesthesiologist wants to meet the person during pregnancy, not during labor. A planned consultation lets them see the latest levels, agree a threshold with the hematologist, and explain the alternatives calmly. Someone who arrives in active labor without recent levels may be asked to wait for a blood result before an epidural can be placed, and that waiting can feel hard. Knowing the reason in advance helps.

The decision belongs to the anesthesiologist on the day, informed by the written plan and fresh laboratory results.

Von Willebrand disease and childbirth: what happens during labor

On the day, the plan moves from paper to practice. If treatment to raise levels is part of it, timing becomes the focus. For a planned cesarean, concentrate or desmopressin is usually given shortly before the operation. For spontaneous labor, the team watches progress and gives treatment at the point the plan specifies, often as delivery approaches or when an epidural is requested.

Vaginal birth is not discouraged. The NHS and the international guideline both treat the mode of delivery as an obstetric decision, made for obstetric reasons, with the bleeding disorder influencing how it is managed rather than whether it happens. Cesarean does not eliminate bleeding risk; it exchanges one kind of bleeding challenge for another.

Two precautions stand out, and both protect the baby rather than the mother. Because a child may inherit the condition, especially from a parent with type 2 or type 3, the team generally avoids:

• Fetal scalp electrodes, which are small clips placed on the baby’s scalp to monitor heart rate, and fetal scalp blood sampling.
• Instrumental delivery with a vacuum device or rotational forceps, which can cause bleeding inside the baby’s head if the baby has low clotting factor.

If assistance is needed, obstetricians weigh a straightforward lift-out with forceps against a cesarean, and the choice depends on the exact circumstances. A prolonged second stage of labor with the baby not descending tends to shift the decision toward cesarean earlier than it might otherwise.

The third stage, when the placenta separates, is where the mother’s own clotting is tested. Active management of this stage with the usual uterine-contracting medicines is standard. The team keeps a closer eye on blood loss, and the hematologist is contactable throughout. A newborn blood sample, often from the umbilical cord, may be sent to check the baby’s levels, although results in newborns are interpreted cautiously because levels are naturally altered around birth.

Von Willebrand postpartum bleeding: the days and weeks after birth

If one message from this article should stick, it is this one. The period after birth, not labor itself, is when people with von Willebrand disease are most likely to run into trouble, and it is when they are least likely to be in hospital.

The reason is the curve described earlier. The protein levels that climbed through pregnancy begin falling within days of delivery and return toward baseline over the following weeks. The international guideline highlights this decline as the mechanism behind delayed postpartum hemorrhage, meaning heavy bleeding that begins or worsens after the first 24 hours, sometimes a week or more after going home. The normal postpartum discharge, called lochia, is expected for several weeks in anyone, so the challenge is recognizing when it has become something more.

The plan for this period usually has three parts. Monitoring: levels may be rechecked before discharge and in the following days, particularly after a cesarean or in type 2 and type 3 disease. Medicine: the guideline suggests an antifibrinolytic for the postpartum period, and people who needed concentrate for delivery may continue it for a number of days as decided by the hematologist. Communication: a direct phone number for the hematology or maternity team, and clear written guidance on what counts as too much bleeding.

A typical trajectory, drawing on guideline descriptions, looks like early vigilance in the first 24 hours when bleeding risk is highest for everyone, continued cover and checks over the first week, then a watchful period through roughly the third to sixth week as levels settle. These are ranges, not promises, and the team sets the specifics.

Breastfeeding is generally compatible with the medicines discussed here, but this is a question for the prescribing clinician, who will weigh the specific medicine and the individual situation. Iron status is also rechecked, because recovering from any blood loss is slower when stores are already low.

Is von Willebrand disease hereditary, and what does that mean for the baby?

Yes, the common forms are inherited, and this shapes several of the delivery precautions already described. MedlinePlus explains that type 1 and most type 2 subtypes follow an autosomal dominant pattern, meaning one altered copy of the gene, from either parent, is enough to cause the condition. Each child of an affected parent has a 50 percent chance of inheriting that copy. Type 3 and type 2N follow a recessive pattern, where a child must inherit an altered copy from both parents to have the condition; a child with one copy is a carrier and usually has no or mild symptoms.

Severity does not pass predictably. A parent with mild type 1 may have a child whose symptoms are milder or more noticeable; the same gene change can behave differently in different family members, and other factors, including blood group, influence protein levels.

For the baby, the implications are mostly about avoiding injury during birth, as covered in the labor section, and about testing. A cord blood sample can give an early indication, but newborn levels are affected by the stress of delivery and are often repeated later in infancy before a diagnosis is made or ruled out. Routine newborn procedures that involve a needle or a small cut, such as the heel-prick screening test, are generally safe but are done with awareness of the possible diagnosis. Where a procedure such as circumcision is being considered, the pediatric team will usually want to know the baby’s status first.

Genetic counseling before or during pregnancy helps parents understand these odds in the context of their own family history. Prenatal diagnostic testing exists but is uncommon for the milder types, and the decision about whether to pursue it rests entirely with the parents and their counselor.

How is acquired von Willebrand disease different, and how is it treated?

Acquired von Willebrand disease is not inherited. It develops when another condition removes, destroys or binds up von Willebrand factor faster than the body can replace it. Causes described by the NIH and Mayo Clinic include certain heart problems where blood is forced through a narrowed valve or a mechanical pump at high shear, some blood and lymph system disorders that produce abnormal antibodies, an underactive thyroid, and certain autoimmune diseases.

It is rare in pregnancy, but it belongs in this article because the question is asked often and because the approach differs in one fundamental way. In inherited disease, the plan centers on replacing or releasing the protein. In acquired disease, the first principle is to treat the underlying cause. When a heart valve problem is corrected or a thyroid condition is managed, von Willebrand factor levels often recover on their own. Where the cause cannot be addressed quickly, or where bleeding needs controlling in the meantime, hematologists may use the same tools described earlier, including concentrate and antifibrinolytics, with the caveat that replaced protein may be consumed quickly if the underlying process is still active. Other approaches, such as treatments aimed at antibodies, are considered in specific circumstances.

Diagnosis can be tricky. Someone with no family history and no bleeding problems in earlier life who develops bruising or heavy bleeding in adulthood prompts the question. In pregnancy, where protein levels are expected to rise, a failure to rise or an unexpected fall can be the clue.

The practical point for an expectant parent is that if acquired disease is suspected, the team expands: the cardiologist, endocrinologist or other specialist managing the root cause becomes part of the planning group alongside hematology and obstetrics.

What people often get wrong about von Willebrand disease in pregnancy

Several beliefs circulate widely enough to deserve direct correction.

“A cesarean is safer because it is controlled.” Not as a rule. Surgery carries its own bleeding risk and a longer period during which levels must be maintained. Guidelines treat the mode of delivery as an obstetric decision; the bleeding disorder changes how a birth is managed, not which kind is chosen.

“Once the baby is out, the risk is over.” The opposite is closer to the truth. The hours and weeks after delivery, as pregnancy-raised levels fall, are the longest window of risk, and the one spent largely at home.

“My levels were fine early in pregnancy, so I am fine for delivery.” An early test is a snapshot of a moving target. The number that guides the delivery plan is the one drawn late in the third trimester.

“Type 1 is mild, so it needs no planning.” Type 1 is often mild, and many people need no specific treatment for a vaginal birth. A minority do not see the expected rise, and some have a bleeding history out of proportion to their numbers. Planning is still needed; it is just often lighter.

“Desmopressin works for everyone with the condition.” It releases stored protein, so it does little in type 3, where there is almost nothing stored, and it is generally avoided in type 2B because of its effect on platelets. Response is tested, not assumed.

“The baby cannot be affected because I am mild.” Severity does not pass predictably, and a child has a 50 percent chance of inheriting a dominant gene change regardless of how mild the parent’s symptoms are, according to MedlinePlus.

“Heavy bleeding after birth is just normal for me.” Heavy bleeding is common with this condition, which is precisely why it should be reported, not normalized. Many diagnoses are made only after a postpartum hemorrhage that could have been anticipated.

Questions to ask your care team

A good consultation is a two-way exchange, and people who arrive with questions tend to leave with a clearer plan. The following are drawn from what hematology and maternity clinicians say they wish patients would ask.

• Which type and subtype do I have, and has it been confirmed with functional testing?
• What were my most recent von Willebrand factor and factor VIII levels, and when will they be rechecked?
• Have I had a desmopressin trial? If so, how did I respond, and is it an option for me in this pregnancy?
• Who is on my team, and is there a written delivery plan in my maternity record that any clinician on duty can read?
• Will I meet the anesthesiologist before labor, and what threshold will they use when deciding about an epidural or spinal?
• If I need treatment to raise my levels, when will it be given, and how long will it continue after birth?
• Which fetal monitoring methods and delivery instruments will be avoided, and what happens if I need help in the second stage of labor?
• What is the plan for the first six weeks after birth? Who do I call, and at what hour, if bleeding seems heavy?
• Will my baby be tested, and when will a result be reliable?
• Are the medicines in my plan compatible with breastfeeding, and who makes that decision?
• Should my iron levels be checked and treated before delivery?
• If I have a history of heavy periods, what should I expect when periods return, and who manages that?

Write the answers down or ask for them in writing. Partners and birth supporters benefit from knowing the plan too, since they are often the ones who notice a change in bleeding at home. None of these questions implies a particular answer; they are prompts for a conversation in which every decision stays with the treating team.

When to call your doctor

Most pregnancies with von Willebrand disease proceed without emergencies, but the team wants to hear early rather than late. Contact your maternity unit, hematology team or emergency services promptly for any of the following.

During pregnancy: any vaginal bleeding; a nosebleed or gum bleed that does not stop with firm pressure after a reasonable time; large unexplained bruises; blood in urine or stool; or a severe headache, visual disturbance or sudden weakness, which need urgent assessment in any pregnancy.

After birth, seek urgent care for:

• Soaking a maternity pad in an hour or less, or passing clots larger than a golf ball.
• Bleeding that was settling and then becomes heavier again, especially in the second or third week.
• Feeling faint, dizzy, unusually breathless, or having a racing heart, which can signal significant blood loss even before the bleeding itself looks alarming.
• Severe abdominal pain, fever, or foul-smelling discharge, which may indicate infection or retained tissue alongside bleeding.
• Any back pain, leg weakness, numbness or difficulty passing urine after an epidural or spinal, which the anesthetic team treats as an emergency.
• Bleeding from a cesarean wound or perineal stitches that does not stop with pressure.

For the baby: unusual bruising, bleeding from the umbilical stump or heel-prick site that does not stop, unusual sleepiness, poor feeding, vomiting or a bulging soft spot on the head should be assessed urgently.

When in doubt, call. Maternity teams would far rather reassure someone over the phone than treat a hemorrhage that was noticed late. Keep the direct number from your plan where you and your supporters can find it, and tell any clinician you see, including dentists and emergency staff, that you have a bleeding disorder.

Frequently asked questions

Can you have a baby if you have von Willebrand disease?

Yes. Von Willebrand disease does not affect fertility and does not prevent a healthy pregnancy or vaginal birth. The condition changes how a birth is managed rather than whether it can happen. With a known diagnosis, a written plan shared between hematology and obstetrics, and close follow-up after delivery, the large majority of pregnancies proceed safely. The main risks cluster around bleeding after birth, which is exactly where planning focuses.

What are the key points of patient education about von Willebrand disease in pregnancy?

Know your type and subtype, because the plan differs for each. Understand that levels rise during pregnancy and fall after birth, so late-pregnancy testing and postpartum vigilance both matter. Learn which medicines are in your plan and why, without changing anything yourself. Tell every clinician about your bleeding disorder. Keep a direct contact number and know the red-flag signs of heavy bleeding. Share the plan with your birth supporter.

How is acquired von Willebrand disease treated?

The first step is treating the condition causing it, such as a heart valve problem, a thyroid disorder or a blood disorder producing abnormal antibodies; levels often recover once the cause is addressed. While that is happening, or if bleeding must be controlled sooner, hematologists may use von Willebrand factor concentrate, antifibrinolytic medicines or treatments aimed at antibodies, chosen case by case. It is rare in pregnancy and always involves the specialist managing the root cause.

What are the management guidelines for von Willebrand disease in pregnancy?

The joint guideline from the American Society of Hematology, ISTH, NHF and WFH recommends multidisciplinary planning, late-pregnancy measurement of von Willebrand factor activity and factor VIII, treatment to reach at least 0.50 IU/mL for delivery and neuraxial anesthesia when needed, and antifibrinolytic medicine in the postpartum period. NHS guidance adds avoiding fetal scalp electrodes and instrumental delivery. All decisions are individualized by the treating team.

Can you have an epidural with von Willebrand disease?

Often, yes. Guidelines suggest an epidural or spinal can be considered when von Willebrand factor activity and factor VIII are at least 0.50 IU/mL at the time of the procedure, with levels kept up while the catheter is in place. Many people with type 1 reach this naturally; others reach it with treatment. In some situations, such as type 2B with low platelets, the anesthesiologist may advise alternatives. The decision is made on the day with fresh results.

How does von Willebrand disease and childbirth planning protect the baby?

Because a child may inherit the condition, the team generally avoids fetal scalp electrodes, fetal scalp blood sampling, vacuum extraction and rotational forceps, all of which can cause bleeding in a baby with low clotting factor. If assisted delivery is needed, the obstetrician weighs a simple lift-out against cesarean. A cord blood sample may be tested, with results interpreted cautiously and often repeated later in infancy before a diagnosis is confirmed.

When is von Willebrand postpartum bleeding most likely?

Two windows matter. The first 24 hours carry the highest bleeding risk for anyone giving birth. For people with von Willebrand disease there is a second, longer window over the following weeks, as pregnancy-raised protein levels fall back toward baseline. Delayed postpartum hemorrhage may begin or worsen a week or more after going home. Soaking a pad in an hour, large clots, or bleeding that settles and returns should prompt an immediate call.

Is von Willebrand disease hereditary?

Yes. Type 1 and most type 2 subtypes are autosomal dominant, so each child of an affected parent has a 50 percent chance of inheriting the gene change. Type 3 and type 2N are recessive, requiring an altered copy from both parents. Severity does not pass predictably; a mildly affected parent can have a child with more noticeable symptoms or none at all. Genetic counseling helps families understand their own odds.

Do all people with type 1 need treatment for delivery?

No. In many people with type 1, levels rise into the normal range by the third trimester, and the guideline suggests that no treatment to raise levels is needed for delivery when activity and factor VIII reach at least 0.50 IU/mL. A minority do not see the expected rise, and some have a bleeding history that outweighs their numbers, so late testing and an individualized plan are still essential. Postpartum monitoring applies to everyone.

Why is desmopressin not used for every type of von Willebrand disease?

Desmopressin works by prompting blood vessel cells to release stored von Willebrand factor. People with type 3 have almost nothing stored, so it does little for them. In type 2B the released protein binds platelets too readily and can lower the platelet count, so guidelines generally advise against it. Response varies even within type 1, which is why a supervised trial outside pregnancy is often done before relying on it.

References

• NHS: Von Willebrand disease
• CDC: About von Willebrand Disease
• MedlinePlus Genetics: Von Willebrand disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.